Cooperative Oligomeric Peptide Combinations Enhance the Predicted Therapeutic Profile of SET-M33.

Authors

Ismael Castanon, Giovanni Cappello, Alessandro Rencinai, Laura Cresti, Eva Tollapi, Chiara Falciani, Alessandro Pini

Published in

Antibiotics (Basel, Switzerland). Volume 15. Issue 6. Jun 09, 2026. Epub Jun 09, 2026.

Abstract

Background/Objectives: Antimicrobial peptides (AMPs) are promising candidates against multidrug-resistant bacteria, although their clinical translation is frequently limited by cytotoxicity. In this study, we investigated whether combinations of structurally related oligomeric analogs could cooperatively enhance bacterial membrane targeting while redistributing the associated cytotoxic burden. Methods: Monomeric, dimeric, and tetrameric AMPs were evaluated through antimicrobial susceptibility testing, checkerboard interaction assays, RAW 264.7 macrophage cytotoxicity assays, and all-atom molecular dynamics simulations, including biased membrane insertion and umbrella sampling analyses. In addition, we introduced the Combinatorial Therapeutic Index (CTI) as an exploratory metric to estimate the predicted reduction in cytotoxic burden associated with peptide combinations. Results: Cytotoxicity varied substantially among oligomeric forms, with larger and more hydrophobic peptides, particularly tetramers, exhibiting the highest cytotoxicity. Additive effects were observed in checkerboard assays involving linear, dimeric, and tetrameric forms, supporting the redistribution of the toxic burden and enabling the beneficial membrane-interaction properties of hydrophobic linear peptides to be leveraged at lower cytotoxic cost. Predicted therapeutic improvement ranged from approximately twofold for the SET-M33:L33 combination to nearly ninefold for the SET-M33:DIM-33:L8 triple combination. Molecular dynamics simulations revealed non-redundant membrane interaction behaviors, with smaller peptides exhibiting deeper membrane insertion and the dimeric form favoring interfacial membrane engagement. Conclusions: These findings support a cooperative formulation strategy in which structurally related SET-M33 oligomers contribute complementary antibacterial functions while reducing the predicted cytotoxic burden. Further experimental validation using direct cytotoxicity assays of complete peptide mixtures will be necessary to confirm the therapeutic potential of these formulations.

PMID:
42353715
Bibliographic data and abstract were imported from PubMed on 14 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.